key: cord-1003544-zyyd4yor
authors: Gasparo, Raoul De; Pedotti, Mattia; Simonelli, Luca; Nickl, Petr; Muecksch, Frauke; Lorenzi, Julio C. C.; Mazzola, Federica; Magrì, Davide; Michalcikova, Tereza; Haviernik, Jan; Honig, Vaclav; Cassaniti, Irene; Percivalle, Elena; Mrazkova, Blanka; Polakova, Natalie; Fortova, Andrea; Tureckova, Jolana; Iatsiuk, Veronika; Di Girolamo, Salvatore; Palus, Martin; Zudova, Dagmar; Bednar, Petr; Bukova, Ivana; Bianchini, Filippo; Mehn, Dora; Nencka, Radim; Strakova, Petra; Pavlis, Oto; Rozman, Jan; Gioria, Sabrina; Sammartino, Josè Camilla; Giardina, Federica; Gaiarsa, Stefano; Hammarström, Qiang Pan; Barnes, Christopher O.; Piralla, Antonio; Bjorkman, Pamela J.; Baldanti, Fausto; Calzolai, Luigi; Nussenzweig, Michel C.; Bieniasz, Paul D.; Hatziioannou, Theodora; Prochazka, Jan; Sedlacek, Radislav; Robbiani, Davide F.; Ruzek, Daniel; Varani, Luca
title: Bispecific antibody prevents SARS-CoV-2 escape and protects mice from disease
date: 2021-01-22
journal: bioRxiv
DOI: 10.1101/2021.01.22.427567
sha: 28c4dac493acf5ed09a423ad467022d8e0a6f089
doc_id: 1003544
cord_uid: zyyd4yor

Neutralizing antibodies targeting the receptor binding domain (RBD) of the SARS-CoV-2 Spike (S) are among the most promising approaches against coronavirus disease 2019 (COVID-19)1,2. We developed a bispecific, IgG1-like molecule based on two antibodies derived from COVID-19 convalescent donors, C121 and C1353. CoV-X2 simultaneously binds two independent sites on the RBD and, unlike its parental antibodies, completely prevents S binding to Angiotensin-Converting Enzyme 2 (ACE2), the virus cellular receptor. Furthermore, CoV-X2 recognizes a broad panel of RBD variants and neutralizes SARS-CoV-2 and the escape mutants generated by the single monoclonals at sub-nanomolar concentrations. In a novel model of SARS-CoV-2 infection with lung inflammation, CoV-X2 protects mice from disease and suppresses viral escape. Thus, simultaneous targeting of non-overlapping RBD epitopes by IgG-like bispecific antibodies is feasible and effective, combining into a single molecule the advantages of antibody cocktails.

broad panel of RBD variants and neutralizes SARS-CoV-2 and the escape mutants generated by 48 the single monoclonals at sub-nanomolar concentrations. In a novel model of SARS-CoV-2 49 infection with lung inflammation, CoV-X2 protects mice from disease and suppresses viral escape. 50

Thus, simultaneous targeting of non-overlapping RBD epitopes by IgG-like bispecific antibodies 51 is feasible and effective, combining into a single molecule the advantages of antibody cocktails. 52 53

The COVID-19 pandemic prompted an unprecedented effort to develop effective countermeasures 54 against SARS-CoV-2. Pre-clinical data and phase III clinical studies indicate that monoclonal 55 antibodies (mAbs) could be effectively deployed for prevention or treatment during the viremic 56 phase of the disease 1,2 . Cocktails of two or more mAbs are preferred over a single antibody for 57 increased efficacy and prevention of viral escape, but this approach increases manufacturing 58 volumes and costs, complicates formulation 4,5 and hinders novel strategies like antibody delivery 59 by viral vectors or by non-vectored nucleic acids 6-8 . Instead, multispecific antibodies embody the 60 advantages of a cocktail within a single molecule. 61

To this avail, we employed structural information 9 and computational simulations to design 62 bispecifics that would simultaneously bind to (i) independent sites on the same RBD and (ii) 63 distinct RBDs on a S trimer. Out of several designs evaluated by atomistic Molecular Dynamics 64 simulations, 4 were produced and CoV-X2 was the most potent neutralizer of SARS-CoV-2 65 pseudovirus (half-maximal inhibitory concentration (IC50) = 0.04 nM (5.8 ng/mL); Extended Data 66 Fig.1 ). CoV-X2 is a human-derived, CrossMAb-format IgG1-like bispecific antibody 10 resulting 67 from the combination of the Fragment antigen binding (Fab) of mAbs C121 and C135, two potent 68 SARS-CoV-2 neutralizers 3 . Structural predictions showed that CoV-X2, but not its parental 69 monoclonals, can bind bivalently to all RBD conformations on the S trimer, preventing ACE2 70 access ( Fig.1a and Extended Data Fig.2) 11 . 71

CoV-X2 bound to RBD (KD = 2.3 nM), S trimer (KD = 0.2 nM), and to several S trimer 72 mutants, including the naturally occurring D614G, residues mutated or adjacent to those mutated 73 in the novel United Kingdom (202012/01 or B.1.1.7; N501Y) and South African variants 74 (501Y.V2; K417N, E484K and N501Y) 12,13 , and the escape mutants of the parental mAbs 14 75

(Extended Data Figs.3 and 4) . 76 CoV-X2 also bound to pre-formed C121/RBD and C135/RBD complexes, thus confirming 98 that both of its arms are functional (Fig.1b,c) . Next, an avidity assay by Surface Plasmon 99 Resonance (SPR) was used to experimentally confirm the computational prediction that CoV-X2 100 can simultaneously engage two sites on the same RBD (Methods, Fig.1d and Extended Data Fig.5) . 101

Avidity occurs when IgGs bind bivalently to antigens, resulting in slower dissociation rates (kd) 102 (Extended Data Fig.5a ). Accordingly, C121 and C135 IgG showed avidity at high antigen 103 concentrations due to intermolecular binding of adjacent RBDs; at lower antigen concentrations 104 the dissociation rate was instead faster since intermolecular binding was prevented by the increased 105 distance between RBD molecules, resulting in loss of avidity. Intramolecular avidity is not possible 106 for C121 and C135 since a single epitope is available on each RBD molecule. By contrast, CoV-107 X2 maintained avidity even at low antigen concentrations, indicating bivalent, intramolecular 108 binding ( Fig.1d and Extended Data Fig.5 ). ELISA assays were then performed to evaluate the 109 ability of CoV-X2 to inhibit the binding of recombinant ACE2 to the S trimer (Fig.1e,f) . In line 110 with the structural information 9 , C135 did not affect the ACE2/S interaction. C121, which occupies 111 the ACE2 binding site on the RBD, prevented ACE2 binding but only partially. By contrast, 112 complete inhibition of ACE2 binding was synergistically achieved in the presence of CoV-X2. 113

To assess the neutralizing ability of CoV-X2 in vitro, we used SARS-CoV-2 114 pseudoviruses 15 . The bispecific neutralized pseudovirus carrying wild type SARS-CoV-2 S at sub-115 nanomolar concentrations (IC50 = 0.04 nM (5.8 ng/mL); IC90 = 0.3 nM (44 ng/mL)), which was 116 similar or better than the parental IgGs and >100-fold better IC50 than the parental Fabs (Fig.1g) . 117

Remarkably, CoV-X2 remained effective against pseudoviruses bearing escape mutations that 118 made them resistant to the individual mAbs ( Fig.1g) 14 . We conclude that the in vitro binding and 119 neutralizing properties of CoV-X2 make it preferable over its parental antibodies. 120

To assess the clinical potential of CoV-X2, we investigated its ability to protect animals 121 from infection and disease. We first developed a novel mouse model, in which human ACE2 122 To evaluate the protective effect of antibodies, hACE2 mice were treated with antibody 153 (150 µg) one day before SARS-CoV-2 challenge and monitored over time (Fig.2d-j) . Upon 154 intranasal infection with 1x10 4 pfu of SARS-CoV-2 (SARS-CoV-2/human/Czech 155 Republic/951/2020), isotype control treated animals showed weight loss starting at 3 dpi, and by 156 8 dpi most animals had lost approximately 25-30% of their body weight reaching humane endpoint 157 (Fig.2e) . Infectious virus could be recovered from the lungs (Fig.2f) , and viral RNA was detected 158 also at distant tissues, such as spleen (Fig.2g) . Lung pathology resembled severe COVID-19 in 159 humans 20 and was characterized by alveolar replacement with infiltrates of immune cells and 160 fibroblasts, thickened septa and activated macrophages with foamy cytoplasm in regions of 161 minimally changed morphology (Fig.2h,i and data not shown) . In contrast, animals treated with 162

CoV-X2 maintained their body weight (P<0.0001 on 4-8 dpi when compared to isotype; Fig.2e) , 163

had reduced viral RNA in the spleen (Fig.2g) and displayed no macro-or histopathological 164 changes (Fig.2h,i) . While infectious virus could be readily recovered from controls (5 of 6), it was 165 only recovered from 1 out of 8 CoV-X2 treated animals (Fig.2f) . Therefore, CoV-X2 protects mice 166 from infection and disease. 167

Since monotherapy with C121 or C135 mAbs leads to virus escape in vitro 14 , we treated 168 hACE2 mice with the individual antibodies and sequenced the virus. Only wild type RBD 169 sequences were obtained from controls (n=10). Instead, the virus in mice treated with C121 170 acquired the mutation E484D (5 of 5 mice that were analyzed on 8 dpi). C121 escape mutations at 171 E484 were observed in vitro 14 . Mutations at this residue, present also in the novel South African 172 variant (501Y.V2), reduce neutralization by human sera more than 10-fold 21 . E484D affects 173 intermolecular H-bonds at the core of the C121/RBD interface (Fig.2j) and it is suggested to 174 increase the RBD affinity for ACE2 22 . Virus with D484 is pathogenic, since 7 out of 9 mice treated 175 with C121 developed disease ( Fig.2e and data not shown). In contrast, and unlike the in vitro 176 results 14 , no virus evasion or pathology were observed in mice treated with C135 (n=5; Fig.2e and 177 data not shown). Similarly, none of the CoV-X2 treated animals (n=8) developed pathology, 6 had 178 wild type RBD sequence, one mouse had a mix of wild type and E484D/N440K sequences and 179 another a mix of wild type and E484D. Thus, in addition to protecting from disease, CoV-X2 180 suppresses virus escape. 181

Monoclonal antibodies targeting the SARS-CoV-2 S are in advanced clinical trials and 182

show promise against COVID-19 1,2 . Concomitant use of multiple antibodies is preferred for 183 increased efficacy and added resistance against viral evasion. Indeed, the virus can escape pressure 184 by a single antibody in vitro and, as shown here, also in animals after only a few days from 185 infection. Moreover, RBD mutations threatening the efficacy of single monoclonals have already 186 been detected in virus circulating in minks and humans 23 , including mutations at the C121 and 187 C135 epitopes (Extended Data Fig.7) . One disadvantage of antibody cocktails is the requirement 188 for twice or more the production capacity than for single mAbs, which is a significant bottleneck 189 during the current pandemic. 

Escape from neutralizing antibodies by SARS-CoV-2 spike protein 246 variants

Measuring SARS-CoV-2 neutralizing antibody activity using 248 pseudotyped and chimeric viruses

Lung Expression of Human ACE2 Sensitizes the Mouse to SARS-CoV-2

A SARS-CoV-2 Infection Model in Mice Demonstrates Protection 252 by Neutralizing Antibodies

Generation of a Broadly Useful Model for COVID-19 Pathogenesis

A Mouse Model of SARS-CoV-2 Infection and Pathogenesis

Histopathological 260 observations in COVID-19: a systematic review

Comprehensive mapping of mutations to the SARS-CoV-2 receptor-263 binding domain that affect recognition by polyclonal human serum antibodies. bioRxiv

Escape from neutralizing antibodies by SARS-CoV-2 spike protein 268 variants

Conceptual Approaches to Modulating Antibody Effector Functions and 270 Circulation Half-Life

Cross-reacting antibodies enhance dengue virus infection in 273 humans

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

Antibody-dependent infection of human macrophages by severe acute 278 respiratory syndrome coronavirus

Anti-severe acute respiratory syndrome coronavirus spike antibodies 280 trigger infection of human immune cells via a pH-and cysteine protease-independent 281 FcγR pathway

Antibody-dependent enhancement of SARS coronavirus infection and its 283 role in the pathogenesis of SARS

Engineering therapeutic bispecific antibodies using CrossMab technology

Extended Data Fig.3 | CoV-X2 and its parental mAbs bind recombinant, isolated RBD and S trimer 346 with low nanomolar affinity. a, Representative SPR traces from which the data in (b) was derived. b

Kinetic parameters for the binding of C121 IgG, C135 IgG, and CoV-X2 to S trimer and RBD

Extended Data Fig.4 | CoV-X2 binds with low-nanomolar affinity to S protein mutants, including 350 some that are not recognized by the parental mAbs C121 and C135. a, SPR-derived binding affinities 351 of CoV-X2, C121 IgG and C135 IgG to several S trimer mutants. b, Mutations tested in (a) are indicated 352 by yellow spheres on the surface representation of the S trimer

V2 variant with increased spread and viral load are in red. The epitopes of C121 (green) and C135

RBD concentration, as expected. kd became faster for the monoclonals (loss of avidity) 367 but less so for the bispecific (avidity maintained due to simultaneous binding to two sites on a single RBD)

Extended Data Fig.6 | Generation of the new AAV-hACE2-transduced mouse model for COVID-19

Western blot 371 analysis detecting hACE2 expression in the lungs of one non-transduced control mouse (Ctrl) and 12 mice 372 transduced with two different doses of AAV-hACE2 viral particles

Lung tissue was collected 1, 2, or 4 weeks (w) post transduction. Histone H3 was used as control for

In order to 376 increase viral titers, viral particles from both cell lysate and PEG-precipitated growth medium were 377 ultracentrifuged in discontinuous iodixanol gradient. The silver-stained SDS-PAGE gel shows 14 378 consecutive fractions: 1-9 represent enriched AAV fractions used for experiments, whereas fractions 10-379 14 are contaminated with proteinaceous cell debris. Iodixanol was chosen as a density gradient medium 380 due to its low toxicity in vivo and its easy removal by ultrafiltration. M is protein marker, * are AAV capsid 381 proteins VP1, VP2, and VP3. d, The amount of AAV particles was estimated by qRT-PCR. The number of 382 genome copies (GC) expressed as log was calculated from a standard curve. From one 15 cm 2 dish, 75 µl 383 with 2.0x10 12 GC/ml were prepared, which is sufficient for hACE2 humanization of 37 mice. e, Kinetic of 384 lung histopathology in SARS-CoV-2 infected ACE2 humanized mice. Hematoxylin and Eosin stained 385 sections showed inflammatory infiltrates composed of lymphocytes, macrophages, neutrophils, and 386 fibroblasts replacing the alveoli. The size of the affected areas increased over time. Alveolar septa were 387 thickened in areas close to infiltrates

Summary of 393 naturally occurring mutations in the C121 (a) or C135 (b) epitopes reported in circulating SARS-CoV-2 394 (as of